Lyell Immunopharma Inc expected to post a loss of 18 cents a share - Earnings Preview
02/05/2025 13:11
Lyell Immunopharma Inc LYEL.OQ LYEL.O is expected to show a fall in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Lyell Immunopharma Inc is for a loss of 18 cents per share. The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Lyell Immunopharma Inc is $0.80, above its last closing price of $0.47. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.13 | -0.17 | -0.20 | Missed | -17.6 |
| Sep. 30 2024 | -0.19 | -0.20 | -0.17 | Beat | 15 |
| Jun. 30 2024 | -0.21 | -0.20 | -0.18 | Beat | 12.2 |
| Mar. 31 2024 | -0.22 | -0.21 | -0.24 | Missed | -14.3 |
| Dec. 31 2023 | -0.21 | -0.23 | -0.20 | Beat | 12.3 |
| Sep. 30 2023 | -0.24 | -0.25 | -0.17 | Beat | 32 |
| Jun. 30 2023 | -0.25 | -0.27 | -0.18 | Beat | 34.1 |
| Mar. 31 2023 | -0.28 | -0.28 | -0.23 | Beat | 18.8 |
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma